Literature DB >> 8873494

Human immunodeficiency virus infection and acquired immunodeficiency syndrome among North American women.

S Cu-Uvin1, T P Flanigan, J D Rich, M D Mileno, K H Mayer, C C Carpenter.   

Abstract

Women constitute the fastest growing segment of adults with acquired immunodeficiency syndrome (AIDS), representing 18% of all cases in the United States in 1994. Heterosexual transmission is now the dominant route by which women are infected. Recent reports indicate that although certain manifestations may be different in women than in men, the rate of clinical progression is similar when they receive comparable medical treatment. Antiretroviral therapy is equally as effective in women as in men. As in men, Pneumocystis carinii pneumonia is the most frequent AIDS-defining diagnosis in women. Candida esophagitis and ulcers secondary to herpes simplex virus are more common in women. Kaposi's sarcoma is rare. The prevalence of humanpapilloma virus infection and cervical neoplasia is increased in HIV-seropositive women. Vaginitis due to candida, trichomonas, and bacterial vaginosis are common findings among human immunodeficiency virus seropositive women. The clinical course and response to therapy in certain sexually transmitted diseases (syphilis and herpes) may be altered. The use of zidovudine during pregnancy and delivery has been associated with a 67.5% reduction in vertical transmission.

Entities:  

Mesh:

Year:  1996        PMID: 8873494     DOI: 10.1016/S0002-9343(96)00063-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

1.  Delays in seeking HIV care due to competing caregiver responsibilities.

Authors:  M D Stein; S Crystal; W E Cunningham; A Ananthanarayanan; R M Andersen; B J Turner; S Zierler; S Morton; M H Katz; S A Bozzette; M F Shapiro; M A Schuster
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

Review 2.  Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.

Authors:  A P Lea; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.